Ann Marie Porreca1, Kaede V Sullivan2, Jason C Gallagher3. 1. Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA, USA. 2. Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 3. Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA, USA. Jason.gallagher@temple.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to investigate the evolution and epidemiology of Klebsiella pneumoniae carbapenemase (KPC)-producing organisms and the current and future treatment options for infections caused by KPC-producing isolates. RECENT FINDINGS: The emergence of resistance in Enterobacteriaceae producing carbapenemases globally has increased the challenges in treating infections caused by these organisms. One of the prominent mechanisms of resistance is the production of KPC enzymes. Infections caused by organisms producing KPCs have limited treatment options and are associated with poor clinical outcomes. The rapid rise of KPC-producing organisms necessitated the use of drugs with pharmacokinetic and toxicity limitations, including polymyxins, tigecycline, fosfomycin, and aminoglycosides. The availability of new beta-lactamase inhibitor combinations that are effective against KPC-producing organisms represent an advance in safety and efficacy. Several agents are currently being studied that have activity against KPC-producing organisms and appear to represent promising additions to our armamentarium. KPC-producing organisms cause infections with high morbidity and mortality. Limited treatment options are available, though new therapies have been developed. Pipeline agents are likely to have a place in therapy for the treatment of infections caused by KPC-producing isolates.
PURPOSE OF REVIEW: The purpose of this review is to investigate the evolution and epidemiology of Klebsiella pneumoniae carbapenemase (KPC)-producing organisms and the current and future treatment options for infections caused by KPC-producing isolates. RECENT FINDINGS: The emergence of resistance in Enterobacteriaceae producing carbapenemases globally has increased the challenges in treating infections caused by these organisms. One of the prominent mechanisms of resistance is the production of KPC enzymes. Infections caused by organisms producing KPCs have limited treatment options and are associated with poor clinical outcomes. The rapid rise of KPC-producing organisms necessitated the use of drugs with pharmacokinetic and toxicity limitations, including polymyxins, tigecycline, fosfomycin, and aminoglycosides. The availability of new beta-lactamase inhibitor combinations that are effective against KPC-producing organisms represent an advance in safety and efficacy. Several agents are currently being studied that have activity against KPC-producing organisms and appear to represent promising additions to our armamentarium. KPC-producing organisms cause infections with high morbidity and mortality. Limited treatment options are available, though new therapies have been developed. Pipeline agents are likely to have a place in therapy for the treatment of infections caused by KPC-producing isolates.
Authors: Antonio T Freire; Vasyl Melnyk; Min Ja Kim; Oleksiy Datsenko; Oleksandr Dzyublik; Felix Glumcher; Yin-Ching Chuang; Robert T Maroko; Gary Dukart; C Angel Cooper; Joan M Korth-Bradley; Nathalie Dartois; Hassan Gandjini Journal: Diagn Microbiol Infect Dis Date: 2010-10 Impact factor: 2.803
Authors: Matthew J Ellington; David M Livermore; Tyrone L Pitt; Lucinda M C Hall; Neil Woodford Journal: J Antimicrob Chemother Date: 2006-08-05 Impact factor: 5.790
Authors: Christoph Lübbert; Norman Lippmann; Thilo Busch; Udo X Kaisers; Tanja Ducomble; Tim Eckmanns; Arne C Rodloff Journal: Am J Infect Control Date: 2014-04 Impact factor: 2.918
Authors: David M Jacobs; Sara DiTursi; Christine Ruh; Rajnikant Sharma; Jonathan Claus; Rashmi Banjade; Gauri G Rao Journal: Int J Antimicrob Agents Date: 2016-06-23 Impact factor: 5.283
Authors: David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: Koh Okamoto; Michael Y Lin; Manon Haverkate; Karen Lolans; Nicholas M Moore; Shayna Weiner; Rosie D Lyles; Donald Blom; Yoona Rhee; Sarah Kemble; Louis Fogg; David W Hines; Robert A Weinstein; Mary K Hayden Journal: Infect Control Hosp Epidemiol Date: 2017-04-11 Impact factor: 3.254
Authors: Phillip J Bergen; Zackery P Bulman; Cornelia B Landersdorfer; Nicholas Smith; Justin R Lenhard; Jürgen B Bulitta; Roger L Nation; Jian Li; Brian T Tsuji Journal: Infect Dis Ther Date: 2015-12-08
Authors: Helio S Sader; Paul R Rhomberg; Sukantha Chandrasekaran; Marisol Trejo; Kelley A Fedler; Linda D Boyken; Daniel J Diekema Journal: J Clin Microbiol Date: 2020-03-25 Impact factor: 5.948
Authors: Marta Hernández-García; Juan Antonio Castillo-Polo; Desirèe Gijón Cordero; Blanca Pérez-Viso; María García-Castillo; Javier Saez de la Fuente; María Isabel Morosini; Rafael Cantón; Patricia Ruiz-Garbajosa Journal: J Clin Microbiol Date: 2022-03-16 Impact factor: 11.677